Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioTime acquires assets of Cell Targeting
March 2011
SHARING OPTIONS:

ALAMEDA, Calif.BioTime Inc. recently acquired the assets of Cell Targeting Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine, for $250,000 in cash. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating, or "painting," these peptides onto the surfaces of therapeutic cells using techniques that do not modify the cell physiology, CTI has produced tissue-specific and disease-specific cell modification agents that the company says have the potential to take cell therapy products to a new level of performance. BioTime will initially provide this technology to its majority owned subsidiary OncoCyte Corp., for its R&D efforts related to genetically modified hES- derived vascular progenitors designed to target and destroy malignant tumors.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.